0.42
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan
Acurx Pharmaceuticals secures patent in India for antibiotics By Investing.com - Investing.com Canada
Acurx Pharmaceuticals secures patent in India for antibiotics - Investing.com
Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Yahoo Finance
Lobbying Update: $20,000 of ACURX PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach - Corsicana Daily Sun
Press Release Distribution & PR Platform - ACCESS Newswire
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Acurx Pharmaceuticals announces resale of 8.4M shares - MSN
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Insider Monkey
ACXP stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... By GuruFocus - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Issues Positive Forecast for ACXP Earnings - Defense World
FY2029 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports 2024 Results and Advances Trials - TipRanks
Acurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress - TipRanks
Earnings call transcript: Acurx Pharmaceuticals Q4 2024 sees narrower EPS loss - Investing.com Canada
ACXP stock touches 52-week low at $0.43 amid market challenges - Investing.com UK
Acurx Pharmaceuticals, Inc Full Year Loss Narrows - Nasdaq
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Yahoo Finance
Earnings Scheduled For March 18, 2025 - Benzinga
Acurx Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Increases By 112.2% - The AM Reporter
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP - Milton Daily Standard
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Announces Closing of $1.1 Million Registered Direct Offering -March 10, 2025 at 05:37 pm EDT - MarketScreener
ACXPAcurx Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - Stock Titan
Dow Dips Over 250 Points; Genesco Shares Plunge After Q4 Results - Benzinga
Why Acurx Pharmaceuticals (ACXP) Shares Are Down 30% - Benzinga
Acurx Pharmaceuticals Launches $1.1 Million Registered Direct Offering; Shares Fall -March 07, 2025 at 10:07 am EST - Marketscreener.com
Nasdaq Gains 100 Points; US Economy Adds Fewer Jobs Than Projected - Benzinga
Acurx Pharmaceuticals stock sinks on $1.1M direct offering - MSN
Acurx Pharmaceuticals Announces $1.1 Million Registered Direct Offering -March 07, 2025 at 08:14 am EST - Marketscreener.com
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decrease in Short Interest - Defense World
ACXP stock touches 52-week low at $0.66 amid market challenges - Investing.com
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - Yahoo Finance
Can Acurx's Antibiotic Revolutionize C. Difficile Treatment? New Microbiome Data Suggests Yes - Stock Titan
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update - Yahoo Finance
Biotech Alert: Searches spiking for these stocks today - TipRanks
Acurx’s ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down - Nasdaq
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the - Digital More
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):